anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A process for preparing the medicine to prevent and treat diabetes, hyperlipomia and obesity includes such steps as proportionally mixing chronmium aminoacitate with filler, disintegrant, lubricant and adhesive and conventionally preparing tablets, particles or capsules. The filler may be starch, emulsified starch, amyline, etc.. The disintegrant may be cross-linked carboxymethylcellulose sodium, starch, etc. The lubricant may be magnesium stearate, talc powder, etc. The adhesive may be starch paste, gelatin or arabic gum, etc. Its advantages are simple preparing process and high curative effect.
Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
The invention belongs to the technical field of veterinary drug preparation. In particular to a veterinary tilmicosin nano-gel breast perfusion agent and a preparation method thereof. The key point of the invention is the preparation process of combining the nanometer preparation and the gel process preparation formulation and the product formula thereof. The breast perfusion agent comprises 0.5-10.0% of tilmicosin, 2.0-20.0% of oil phase, 1.0-5.0% of surfactant, 0.1-4.0% of gel material, 0.5-5.0% of cross-linking agent, 0.001-0.05% of preservative and the balance of water for preparation in terms of W/V. The invention overcomes the defect of single nano-drug front-end release, and can effectively avoid the phenomenon of tilmicosin nanoparticle burst release. The gel film also has the advantages of good adhesion of emerging gel mucous membrane, promotion of wound healing and maintenance of local internal environment, and the treatment effect of tilmicosin on staphylococcus aureus mastitis is obviously improved. The method is beneficial to reducing the using amount of tilmicosin and the culture cost.
A majority of the research in patients with chronic ischemic heart disease and left ventricular dysfunction deals with increasing patient survival rates and years. Very little research has focused on patients' perceptions of living with this chronic debilitating disease. The purpose of this naturalistic, prospective study is to assess the Health Related Quality of Life (HRQOL), anginal symptoms and symptom distress experienced by patients with chronic ischemic heart disease and left ventricular dysfunction. The relationship between underlying cardiac condition, anginal symptoms, symptom distress and HRQOL will be examined. The trend in HRQOL across time versus treatment group will be evaluated. The question, does HRQOL, anginal frequency and symptom distress at baseline predict mortality and cardiac related hospitalization during the year following assessment will also be addressed.

Patients who are enrolled in protocols in the Cardiology Branch of the National Heart Lung and Blood Institute (NHLBI) and diagnosed with chronic ischemic heart disease and left ventricular dysfunction will be asked to participate in this HRQOL study. Patients will complete measures of HRQOL (Medical Outcomes Short Form 36 Survey; Minnesota Living with Heart Failure Questionnaire) and symptom measures (anginal frequency subscale of the Seattle Angina Questionnaire; cardiopulmonary subscale of the Heart Transplant Symptom Checklist). Underlying cardiac condition will be assessed using exercise thallium imaging parameters (METS and perfusion defects) and positron emission tomography (PET) imaging parameter (viability). A sample size of 90 subjects is desired for this study. Data will be analyzed using multivariate statistics. It is expected that this study will provide new information regarding how patients with ischemic heart disease and left ventricular function feel their chronic illness and its corresponding treatment(s) affects their HRQOL.
Each subject will receive 532 nm KTP laser treatment for their lower extremity spider veins in at least 2, and up to 4, separate areas. Subjects will receive 2 laser treatments spaced 12 weeks apart. Subjects will be followed for 24 weeks (12 weeks after the final laser treatment). Efficacy will be evaluated by blinded independent physician assessment of improvement in treated spider veins using digital photographs taken at baseline and the final follow-up visit by a third-party medical photography service. In addition, efficacy will be evaluated by the Investigator's mean global assessment of improvement and the subject's mean assessment of improvement. Safety will be evaluated by continuous monitoring of adverse events (AEs) and measuring pain associated with laser treatment.
PURPOSE:To provide a carcinostatic agent having low toxicity and excellent carcinostatic effect, by bonding a carcinostatic substance to a divinyl ether- maleic anhydride copolymer having a specific molecular weight, and using the bonded product as an active component. CONSTITUTION:The objective carcinostatic agent contains 5-40wt% active component comprising the polymeric compound of formula I (R is residue capable of giving carcinostatic activity, e.g. the group of formula II, etc.; n is a number corresponding to the molecular weight of 2,000-15,000 of the divinyl ether- maleic anhydride copolymer bonded to R) and its salt. The agent has excellent slow-releasing property and low toxicity, and furthermore, excellent casrcinostatic effect compared with the single use of the carcinostatic substance, by the synergistic effect with the copolymer having carcinostatic activity by itself. The compound of formula I can be prepared by reacting the copolymer of formula IIIwith a carcinostatic substance (e.g. 5-fluorouridine) in an organic solvent such as N-methylpyrrolidone in the presence of a catalyst such as triethylamine, hydrolyzing the reaction product, and if necessary, converting to a salt.
Betong chicken (KU line) is a slow-growing Thai native chicken used for meat production. The objectives of this study were to identify polymorphisms of the calpain1 (CAPN1) and calpain3 (CAPN3) genes and to investigate their effects on growth, carcass, and meat quality traits in Betong chickens (KU line). A sample of 252 Betong chickens (KU line) was screened for CAPN1 and CAPN3 polymorphisms. The polymorphisms of CAPN1 were detected using gel electrophoresis and DNA sequencing, whereas the polymorphisms of CAPN3 were identified using restriction fragment length polymorphism. Polymorphisms were detected in both CAPN1 (AA, AB, and BB genotypes) and CAPN3 (CC, CT, and TT genotypes). The frequency of the B allele was higher than for the A allele (0.78 and 0.22, respectively) in CAPN1, while the C allelic frequency was higher than for the T allele (0.54 and 0.46, respectively) in CAPN3. The CAPN1 genotype and the combination of the CAPN1 and CAPN3 genotypes could be used as genetic markers for meat lightness. The CAPN3 could be useful for increasing body weight, live weight, and breast meat weight in Betong chickens (KU line).
Subjects randomized to the prehabilitation group will undergo 6 weeks of individualized exercise therapy, including a 1-week ramp-up period (3 sessions) conducted at the VAPAHCS rehabilitation facility. Subjects will then exercise primarily at home, with an in-clinic exercise session repeated weekly for the duration of their participation. These sessions will be individualized based on tolerance and in accordance with standardized guidelines, but will generally consist of 45-60 min of supervised exercise that combines aerobic and resistance training, including warm-up and cool-down. Throughout the study, subjects will be asked to perform 30 minutes of daily unsupervised aerobic exercise of their choice, with an emphasis on improving walking performance at home. Guidelines for patient monitoring, safety, and prescription outlined by the American Heart Association, American College Sports Medicine, and American Association of Cardiovascular and Pulmonary Rehabilitation will be followed.
Monitor patients closely for respiratory depression when initiating therapy and following dosage increases with Remifentanil Hydrochloride for injection and adjust the dosage accordingly [see Warnings and Precautions (5.2)].

Remifentanil Hydrochloride for injection is for IV use only. Continuous infusions of Remifentanil Hydrochloride for injection should be administered only by an infusion device. The injection site should be close to the venous cannula and all IV tubing should be cleared at the time of discontinuation of infusion.

Remifentanil Hydrochloride for injection should not be administered without dilution.

Consider an alternative to Remifentanil Hydrochloride for injection for patients taking mixed agonist/antagonist and partial agonist opioid analgesics due to reduced analgesic effect or potential withdrawal symptoms. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Remifentanil Hydrochloride for injection if patient is not responding appropriately to treatment.

Discard unused portion.
UNLABELLED: Effective and atraumatic removal of a soft lens nucleus requires different surgical techniques compared to phacoemulsification of a dense nucleus.
PURPOSE: This study was conducted to develop a non-ultrasound technique for emulsification of a soft lens nucleus.
MATERIAL AND METHODS: Fifty-seven patients (57 eyes) underwent surgery. In 23 cases, early or immature cataracts were detected, and in 34 cases, lens removal was performed for refractive purposes in high myopia and complex myopic astigmatism. Phacoemulsifier Centurion Vision System (Alcon Laboratories, Inc., USA) was used for the surgery. Aspiration of soft lens nucleus was done using a rotational technique. The following aspects were evaluated in the course of the surgery: the volume of the required irrigation solution, and the frequency needing to involve ultrasound for complete emulsification of the lens nucleus. Intraoperative and postoperative complications were also assessed.
RESULTS: The surgery was uneventful in all cases. There were no violations of the integrity of capsulorhexis edge. The need for short pulses of minimal power ultrasound during the removal of the soft lens using this technique arose only in 11 (19.3%) cases. The effective ultrasound time was less than 1 second. The required volume of irrigation solution was 33.0 (24.0; 43.0) ml, which does not differ significantly from that in ultrasonic phacoemulsification.
CONCLUSIONS: The use of modern phacoemulsifiers providing a high vacuum level allows successful removal of a soft lens without using ultrasound, which prevents its negative impact on the ocular tissues. The use of adequate surgical techniques, including the optimal direction of rotation of the lens nucleus in the rotational technique, improves the efficiency of soft lens nucleus removal.
The outbreak of a new highly contagious and life-threatening infective disease was first reported in China in December 2019. Regardless of the undertaken containing measures, its spreading could not be effectively stopped and currently we are confronting the pandemic diffusion of a newly identified Coronavirus (SARS-CoV-2) (1). This causes a systemic disease, known as (Coronavirus Disease-19) COVID-19, characterised by a broad spectrum of clinical manifestations, including ineffective hyper-inflammation and severe pneumonia, with provisional epidemiologic data indicating a mortality rate of 0.1-15% (2). Do to the lack of vaccination, specific anti-virus sera or monoclonal antibodies, the therapeutic efforts to limit COVID-19 mostly rely on the empirical use of anti-viral drugs. Therefore, being the option of an active immunisation not available and because of the controversial efficacy of the available anti-viral therapies (3), we suggest the option of a passive immunisation for those patients who are infected with the new coronavirus and present dyspnea or a poor prognosis. The use of convalescent plasma, i.e. plasma obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection, could provide a rapid protection, limiting the observed evolution of COVID-19 towards life-threating manifestations (7-9).

When carried on according to standardised measures, the transfusion of plasma is highly safe (10-11) and we assume that products containing anti- SARS-CoV- 2 antibodies will provide the recipients a passive immunity through different mechanisms, including viral neutralisation, antibody-dependent cellular cytotoxicity and/or phagocytosis.
The physician should read the "PRECAUTIONS" section when considering the use of sucralfate oral suspension in pregnant or pediatric patients, or patients of childbearing potential. 

Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration. 

Episodes of hyperglycemia have been reported in diabetic patients. Close monitoring of glycemia in diabetic patients treated with Sucralfate Oral Suspension is recommended. Adjustment of the anti-diabetic treatment dose during the use of Sucralfate Oral Suspension might be necessary. 

Special Populations: Chronic Renal Failure and Dialysis Patients 

When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of sucralfate and aluminum-containing products adequately excrete aluminum in the urine. Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Sucralfate should be used with caution in patients with chronic renal failure.
FIELD: medicine, biotechnology. SUBSTANCE: invention relates to methods of preparing natural anticoagulating agents that inhibit thrombin activity. An aqueous solution of the dried leeches is heated on the boiling water-bath for 3-15 min, centrifuged and supernatanat is subjected for gel-filtration through Sephadex G-25. The first peak is collected, bound with blood plasma kallikrein immobilized on water-insoluble carrier, nonbound part is collected and solution is evaporated up to the dry matter. The end product can be used in medicine, veterinary science. EFFECT: high quality of hirudine.
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
Group B will consist of 30 subjects. In addition to the same hormone stimulation "patch protocol" as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection.
Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
OBJECTIVE: E26 transformation-specific (ETS) factors have emerged as key mediators underlying human tumorigenesis. Here, we sought to characterize the expression pattern, biological roles, and clinical significance of ETS Variant Transcription Factor 5 (ETV5) in head neck squamous cell carcinoma (HNSCC).
SUBJECTS AND METHODS: ETV5 expression pattern in HNSCC was determined by bioinformatics interrogations and immunohistochemical staining in primary samples. The associations between its abundance with clinicopathological parameters, and patient survival were evaluated. Colony formation, CCK-8, flow cytometry, wound healing, and Transwell invasion assays, as well as xenograft models, were utilized to determine the phenotypic changes after ETV5 silencing in vitro and vivo. The potential binding of ETV5 in the Slug promoter was determined by ChIP-qPCR.
RESULTS: ETV5 was significantly overexpressed in HNSCC samples. Its overexpression is significantly associated with aggressiveness features and reduced survival. ETV5 knockdown significantly inhibited cell proliferation, migration, invasion, and induced apoptosis in vitro, and impaired tumor growth in vivo. Moreover, ETV5-activated Slug transcription by binding its promoter region in HNSCC cells. Patients with ETV5highSlughigh had the worst survival across multiple HNSCC cohorts.
CONCLUSIONS: Our findings reveal that ETV5 serves as a novel prognostic biomarker and putative oncogene for HNSCC progression likely by activating Slug transcription.
In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
The present invention relates to methods and compositions for regulating serum phosphate or phosphate homeostasis. More specifically, the present invention relates to methods and compositions for increasing or decreasing serum phosphate levels for the treatment and/or prevention of a variety of phosphate-related diseases by modulating the activity or expression of FRP 4, FGF 23 and PHEX. The methods of the invention are useful for increasing phosphate re-absorption or serum phosphate by delivering to a subject an agent that inhibits the activity of FGF 23 or FRP-4 or for decreasing phosphate re-absorption or serum phosphate by delivering to a subject an agent that enhances the activity FGF 23 or FRP-4 or inhibits the activity of PHEX. Also provided are methods for modulating renal phosphate transport, alleviating oncogenic osteomalacia-associated symptoms, treating phosphate homeostasis-related disease and modulating the phenotype of a neoplastic cell associated with OOM cell or a cell associated with phosphate homeostasis. In addition, the invention provides methods for detecting and monitoring expression of one or more of the FRP 4, FGF 23 and PHEX gene(s) or proteins. Finally, the invention provides methods for screening candidate agents to identify compositions that modify the activity or expression of FRP 4, FGF 23 and PHEX.
rganic and inorganic compounds of vanadium have been successfully used for the treatment of diabetes and virulent diseases. Int he present invention. The composition of three new vanadium (III) complexes is described, one with aminoacid cystein, one with the pseudopeptide N-(2-mercaptopropionyl)-glycine and their therapeutic activity for the treatment of diabetes and virulent diseases.The above complexes were tested to rats that were provided with alloxane for becoming diabetic and with benzopyrene for inducing cancer formation, in daily doses of 0.5 mg V/kg body weight provided orally. Furthermore, the toxicity of the complex of V-cystein was tested with the provision of a dose of 18 mg V/kg body weight orally.The results have shown that the reange of therapeutic treatment of both complexes starts from daily doses of 0,5 mg V/kg body weight and is very satisfactory in doses of 5 kg V/kg body weight for both nosological entities. The results also showed that for virulent diseases, treatment with the vanadium -cystein complex is also more effective and exhibits no toxicity, even for daily doses of 18 mg vanadium per body weight. From the above it derives that the preparation of these complexes and their oral or other provision in non-toxic concentrations is effective for the therapy of diabetes and virulent diseases in humans.
Health related quality of life is becoming an increasingly important topic as medical advancements continue to increase life expectancies in various illnesses. Quality of life (QoL) encompasses the physical, psychological, and social well-being of a person. Studies focusing on health related QoL show that providers have a limited understanding of the QoL of their patients, demonstrating a need for further research. Mortality rates in pediatric intestinal failure (PIF) have significantly dropped over the past 3-4 decades and long-term morbidity rather than survival has come into focus as the outcome of interest. However, there remains a significant knowledge gap regarding the specific factors that contribute to QoL among PIF patients and their families. Insight into the challenges these patients face can promote enhanced support services and psycho-education for caregivers of these children as well as help to tailor medical and surgical treatment with a focus on improved QoL. Due to the rare nature of PIF, and despite a recent bloom in multidisciplinary PIF centers, experience is limited in individual centers and a multi-site study with a robust and diverse patient population is optimal to study QoL in pediatric intestinal failure.
Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
Defined by self-report and urine nicotine \>30 ng/ml and/or urine cotinine \>50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.